BSX
$44.39+0.57%
as of close, Oct 16, 2026
☾ AH $44.39 +0.57%
Boston Scientific CorporationStock · HealthcareS&P 500 Equal Weight 0.2%S&P 500 0.10%Russell 1000 0.09%US Stock Market 0.09%Russell 3000 0.09%MSCI World 0.08%MSCI ACWI 0.07%
BSX SEC filings (2026)
CIK 885725 · Surgical & Medical Instruments & Apparatus (SIC 3841) · incorporated in DE · fiscal year ends in December
4,791 filings on EDGAR since 1995 · 36 annual, 97 quarterly, 430 current · financial statements · earnings
Latest 10-K
Feb 17, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 3, 2026
quarter to Jun 30, 2026
Latest 8-K
Oct 7, 2026
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Last earnings release
Jul 29, 2026
$0.86 vs $0.83 · ▼ 0.0%
Filings on file
4,791
since 1995, 3,692 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 78-K8-K · Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerDirectors or officers; compensation; Other events
September 2026
- Sep 238-K8-K · Directors or officers; compensation
- Sep 88-K8-K · Material cybersecurity incident
August 2026
- Aug 268-K8-K · Other events
- Aug 25Insider buyMorano Susan E (Director) bought 2,040 shares for $100K at $49.22
- Aug 5Insider buyHabiger David C (Director) bought 2,100 shares for $100K at $47.59
- Aug 4Insider buyHabiger David C (Director) bought 140 shares for $6,802 at $48.59
- Aug 3ReportQuarterly report, Q2 2026 — revenue $5.44B (+8% y/y), net income $905.0M, EPS $0.61
- Aug 3Insider buyMahoney Michael F (Chairman, President & CEO · Director) bought 186,240 shares for $9.0M at $48.33
- Aug 3Insider buyHabiger David C (Director) bought 1,042 shares for $50K at $48.07
July 2026
- Jul 31Insider buyLUDWIG EDWARD J (Director) bought 5,000 shares for $227K at $45.48
- Jul 29EarningsEarnings release — EPS $0.86 vs $0.83 est. (+3.6%); revenue $5.44B (+8% y/y) 0.0%
- Jul 278-K8-K · Exit or disposal costs
May 2026
- May 20Insider buyLUDWIG EDWARD J (Director) bought 3,580 shares for $203K at $56.68
- May 20Insider buyHabiger David C (Director) bought 2,250 shares for $126K at $55.92
- May 20Insider buyPegus Cheryl (Director) bought 1,770 shares for $100K at $56.49
- May 19Insider buyHabiger David C (Director) bought 2,200 shares for $125K at $56.95
- May 188-K8-K · Boston Scientific enters into $2 billion accelerated share repurchase agreementOther events
- May 188-K8-K · Boston Scientific announces strategic investment in MiRus LLCOther events
- May 58-K8-K · Charter, bylaws or fiscal-year change; Shareholder vote results
- May 1ReportQuarterly report, Q1 2026 — revenue $5.20B (+12% y/y), net income $1.34B, EPS $0.90
April 2026
March 2026
- Mar 308-K8-K · HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolismOther events
- Mar 18ProxyProxy · Additional proxy materials
- Mar 18ProxyProxy · Proxy statement
- Mar 18ProxyProxy · Annual report to shareholders
- Mar 6ProxyProxy · Preliminary proxy statement
February 2026
- Feb 268-K8-K · Material definitive agreement; Termination of a material agreement; New financial obligation
- Feb 238-K8-K · Boston Scientific elects Cathy Smith and Christophe Weber to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure; Other events
- Feb 17ReportAnnual report, FY2025 — revenue $20.07B (+20% y/y), net income $2.89B, EPS $1.94
- Feb 58-K8-K · Directors or officers; compensation
- Feb 4EarningsEarnings release — EPS $0.80 vs $0.78 est. (+2.6%); revenue $5.29B (+16% y/y) 17.6%
- Feb 2Insider saleMahoney Michael F (Chairman, President & CEO · Director) sold 160,901 shares for $15.0M at $93.49–$94.06 under a 10b5-1 plan
January 2026
- Jan 158-K8-K · Material definitive agreement
- Jan 158-K8-K · Boston Scientific announces agreement to acquire Penumbra, Inc.Regulation FD disclosure
November 2025
October 2025
- Oct 238-K8-K · Directors or officers; compensation
- Oct 22EarningsEarnings release — EPS $0.75 vs $0.71 est. (+5.6%); revenue $5.07B (+20% y/y) 4.0%
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $15.0M in 1 sale and bought $10.0M in 10 purchases; 153 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Aug 25, 2026Form 4 | Morano Susan EDirectorBought · $100K · 2,040 sh |
| Aug 5, 2026Form 4 | Habiger David CDirectorBought · $100K · 2,100 sh |
| Aug 4, 2026Form 4 | Habiger David CDirectorBought · $6,802 · 140 sh |
| Aug 3, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorBought · $9.0M · 186,240 sh |
| Aug 3, 2026Form 4 | Habiger David CDirectorBought · $50K · 1,042 sh |
| Jul 31, 2026Form 4 | LUDWIG EDWARD JDirectorBought · $227K · 5,000 sh |
| May 20, 2026Form 4 | LUDWIG EDWARD JDirectorBought · $203K · 3,580 sh |
| May 20, 2026Form 4 | Habiger David CDirectorBought · $126K · 2,250 sh |
| May 20, 2026Form 4 | Pegus CherylDirectorBought · $100K · 1,770 sh |
| May 19, 2026Form 4 | Habiger David CDirectorBought · $125K · 2,200 sh |
| Feb 2, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorSold · $15.0M · 160,901 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 153 transactions
| Date | Insider |
|---|---|
| Sep 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $27K · 567 sh |
| Sep 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 1,171 sh |
| Sep 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 1,171 sh |
| Aug 11, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOOther · $150K · 2,930 sh |
| Aug 10, 2026Form 4 | Monson JonathanEVP and CFOOther · $500K · 9,908 sh |
| Aug 3, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorOther · $1.1M · 22,119 sh |
| Jul 31, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyOther · $3.0M · 64,198 sh |
| Jul 1, 2026Form 4 | Monson JonathanEVP and CFOTax withholding · $43K · 1,010 sh |
| Jul 1, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · $0 · 2,087 sh |
| Jul 1, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · Restricted Stock Units · $0 · 2,087 sh |
| May 28, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorGift · $0 · 386,755 sh |
| May 7, 2026Form 4 | Smith Cathy RDirectorAward · Deferred Stock Units · $0 · 6,009 sh |
| May 7, 2026Form 4 | Morano Susan EDirectorAward · $0 · 5,081 sh |
| May 7, 2026Form 4 | Pegus CherylDirectorAward · Deferred Stock Units · $0 · 5,081 sh |
| May 7, 2026Form 4 | Habiger David CDirectorAward · $0 · 3,800 sh |
| May 7, 2026Form 4 | LUDWIG EDWARD JDirectorAward · $0 · 3,800 sh |
| May 7, 2026Form 4 | Mega Jessica LDirectorAward · $0 · 3,800 sh |
| May 7, 2026Form 4 | WICHMANN DAVID SDirectorAward · $0 · 3,800 sh |
| May 7, 2026Form 4 | Zane Ellen MDirectorAward · $0 · 3,800 sh |
| May 7, 2026Form 4 | Weber Christophe PierreDirectorAward · $0 · 2,907 sh |
| May 7, 2026Form 4 | Weber Christophe PierreDirectorAward · Deferred Stock Units · $0 · 2,660 sh |
| May 2, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACTax withholding · $57K · 1,007 sh |
| May 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $49K · 872 sh |
| May 2, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · $0 · 2,102 sh |
| May 2, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · Restricted Stock Units · $0 · 2,102 sh |
| May 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 1,802 sh |
| May 2, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 1,802 sh |
| Mar 2, 2026Form 4 | Smith Cathy RDirectorAward · Deferred Stock Units · $0 · 879 sh |
| Mar 2, 2026Form 4 | Weber Christophe PierreDirectorAward · $0 · 879 sh |
| Mar 2, 2026Form 4 | Morano Susan EDirectorAward · $0 · 24 sh |
| Mar 2, 2026Form 4 | Pegus CherylDirectorAward · Deferred Stock Units · $0 · 24 sh |
| Mar 1, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOTax withholding · $29K · 372 sh |
| Mar 1, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · $0 · 838 sh |
| Mar 1, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · Restricted Stock Units · $0 · 838 sh |
| Feb 19, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACOther · $519K · 6,851 sh |
| Feb 16, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorTax withholding · $588K · 7,865 sh |
| Feb 16, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyTax withholding · $135K · 1,806 sh |
| Feb 16, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACTax withholding · $92K · 1,229 sh |
| Feb 16, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryTax withholding · $67K · 890 sh |
| Feb 16, 2026Form 4 | Monson JonathanEVP and CFOTax withholding · $33K · 440 sh |
| Feb 16, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $25K · 339 sh |
| Feb 16, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerTax withholding · $22K · 291 sh |
| Feb 16, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOTax withholding · $21K · 283 sh |
| Feb 16, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · $0 · 16,265 sh |
| Feb 16, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · Restricted Stock Units · $0 · 16,265 sh |
| Feb 16, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · $0 · 3,960 sh |
| Feb 16, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · Restricted Stock Units · $0 · 3,960 sh |
| Feb 16, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · $0 · 2,546 sh |
| Feb 16, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · Restricted Stock Units · $0 · 2,546 sh |
| Feb 16, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · $0 · 1,839 sh |
| Feb 16, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · Restricted Stock Units · $0 · 1,839 sh |
| Feb 16, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · $0 · 990 sh |
| Feb 16, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · Restricted Stock Units · $0 · 990 sh |
| Feb 16, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · $0 · 990 sh |
| Feb 16, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · Restricted Stock Units · $0 · 990 sh |
| Feb 16, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 905 sh |
| Feb 16, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 905 sh |
| Feb 16, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · $0 · 637 sh |
| Feb 16, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · Restricted Stock Units · $0 · 637 sh |
| Feb 14, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorTax withholding · $597K · 7,990 sh |
| Feb 14, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyTax withholding · $149K · 1,990 sh |
| Feb 14, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACTax withholding · $115K · 1,535 sh |
| Feb 14, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryTax withholding · $67K · 895 sh |
| Feb 14, 2026Form 4 | Monson JonathanEVP and CFOTax withholding · $35K · 470 sh |
| Feb 14, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $34K · 449 sh |
| Feb 14, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerTax withholding · $25K · 329 sh |
| Feb 14, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOTax withholding · $22K · 296 sh |
| Feb 14, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · $0 · 16,524 sh |
| Feb 14, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · Restricted Stock Units · $0 · 16,524 sh |
| Feb 14, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · $0 · 4,362 sh |
| Feb 14, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · Restricted Stock Units · $0 · 4,362 sh |
| Feb 14, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · $0 · 3,173 sh |
| Feb 14, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · Restricted Stock Units · $0 · 3,173 sh |
| Feb 14, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · $0 · 1,851 sh |
| Feb 14, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · Restricted Stock Units · $0 · 1,851 sh |
| Feb 14, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 1,190 sh |
| Feb 14, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 1,190 sh |
| Feb 14, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · $0 · 1,124 sh |
| Feb 14, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · Restricted Stock Units · $0 · 1,124 sh |
| Feb 14, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · $0 · 1,058 sh |
| Feb 14, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · Restricted Stock Units · $0 · 1,058 sh |
| Feb 14, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · $0 · 661 sh |
| Feb 14, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · Restricted Stock Units · $0 · 661 sh |
| Feb 13, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorTax withholding · $9.9M · 132,099 sh |
| Feb 13, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyTax withholding · $2.5M · 33,104 sh |
| Feb 13, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACTax withholding · $1.9M · 25,150 sh |
| Feb 13, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryTax withholding · $956K · 12,792 sh |
| Feb 13, 2026Form 4 | Monson JonathanEVP and CFOTax withholding · $59K · 788 sh |
| Feb 13, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOTax withholding · $52K · 690 sh |
| Feb 13, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerTax withholding · $15K · 200 sh |
| Feb 13, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $15K · 199 sh |
| Feb 13, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorAward · $0 · 264,380 sh |
| Feb 13, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyAward · $0 · 69,796 sh |
| Feb 13, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACAward · $0 · 50,760 sh |
| Feb 13, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryAward · $0 · 29,608 sh |
| Feb 13, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · $0 · 8,832 sh |
| Feb 13, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · Restricted Stock Units · $0 · 8,832 sh |
| Feb 13, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · $0 · 2,797 sh |
| Feb 13, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · Restricted Stock Units · $0 · 2,797 sh |
| Feb 13, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · $0 · 2,237 sh |
| Feb 13, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · Restricted Stock Units · $0 · 2,237 sh |
| Feb 13, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · $0 · 1,766 sh |
| Feb 13, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · Restricted Stock Units · $0 · 1,766 sh |
| Feb 13, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · $0 · 1,413 sh |
| Feb 13, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · Restricted Stock Units · $0 · 1,413 sh |
| Feb 13, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · $0 · 1,118 sh |
| Feb 13, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · Restricted Stock Units · $0 · 1,118 sh |
| Feb 13, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · $0 · 588 sh |
| Feb 13, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · Restricted Stock Units · $0 · 588 sh |
| Feb 13, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 500 sh |
| Feb 13, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 500 sh |
| Feb 12, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorTax withholding · $491K · 6,626 sh |
| Feb 12, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyTax withholding · $119K · 1,612 sh |
| Feb 12, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACTax withholding · $97K · 1,302 sh |
| Feb 12, 2026Form 4 | Monson JonathanEVP and CFOTax withholding · $42K · 573 sh |
| Feb 12, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryTax withholding · $36K · 488 sh |
| Feb 12, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsTax withholding · $34K · 457 sh |
| Feb 12, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerTax withholding · $25K · 338 sh |
| Feb 12, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOTax withholding · $18K · 242 sh |
| Feb 12, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorAward · Stock Option (Right to Buy) · $0 · 131,329 sh |
| Feb 12, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorAward · Restricted Stock Units · $0 · 55,652 sh |
| Feb 12, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyAward · Stock Option (Right to Buy) · $0 · 43,776 sh |
| Feb 12, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACAward · Stock Option (Right to Buy) · $0 · 35,817 sh |
| Feb 12, 2026Form 4 | Monson JonathanEVP and CFOAward · Stock Option (Right to Buy) · $0 · 27,857 sh |
| Feb 12, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyAward · Restricted Stock Units · $0 · 18,550 sh |
| Feb 12, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryAward · Stock Option (Right to Buy) · $0 · 17,510 sh |
| Feb 12, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACAward · Restricted Stock Units · $0 · 15,178 sh |
| Feb 12, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · $0 · 13,704 sh |
| Feb 12, 2026Form 4 | Mahoney Michael FChairman, President & CEO · DirectorExercise or conversion · Restricted Stock Units · $0 · 13,704 sh |
| Feb 12, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsAward · Stock Option (Right to Buy) · $0 · 11,939 sh |
| Feb 12, 2026Form 4 | Monson JonathanEVP and CFOAward · Restricted Stock Units · $0 · 11,805 sh |
| Feb 12, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerAward · Stock Option (Right to Buy) · $0 · 11,143 sh |
| Feb 12, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryAward · Restricted Stock Units · $0 · 7,420 sh |
| Feb 12, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOAward · Restricted Stock Units · $0 · 6,071 sh |
| Feb 12, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOAward · Stock Option (Right to Buy) · $0 · 5,584 sh |
| Feb 12, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsAward · Restricted Stock Units · $0 · 5,059 sh |
| Feb 12, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerAward · Restricted Stock Units · $0 · 4,722 sh |
| Feb 12, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · $0 · 3,462 sh |
| Feb 12, 2026Form 4 | Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyExercise or conversion · Restricted Stock Units · $0 · 3,462 sh |
| Feb 12, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · $0 · 2,692 sh |
| Feb 12, 2026Form 4 | Butcher Arthur CEVP& Grp Pres, MedSurg & APACExercise or conversion · Restricted Stock Units · $0 · 2,692 sh |
| Feb 12, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · $0 · 1,442 sh |
| Feb 12, 2026Form 4 | Brown Vance REVP, GC and Corp. SecretaryExercise or conversion · Restricted Stock Units · $0 · 1,442 sh |
| Feb 12, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · $0 · 1,154 sh |
| Feb 12, 2026Form 4 | Monson JonathanEVP and CFOExercise or conversion · Restricted Stock Units · $0 · 1,154 sh |
| Feb 12, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · $0 · 1,058 sh |
| Feb 12, 2026Form 4 | O'Connor Padraig AndrewEVP, Global OperationsExercise or conversion · Restricted Stock Units · $0 · 1,058 sh |
| Feb 12, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · $0 · 961 sh |
| Feb 12, 2026Form 4 | O'Sullivan MiriamSVP, Chief HR OfficerExercise or conversion · Restricted Stock Units · $0 · 961 sh |
| Feb 12, 2026Form 4 | Woodworth EmilySVP, Global Controller and CAOExercise or conversion · $0 · 481 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 24 filings
| Filed | What it is |
|---|---|
| Oct 7, 20268-K | Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerDirectors or officers; compensation; Other events |
| Sep 23, 20268-K | Directors or officers; compensation |
| Sep 8, 20268-K | Material cybersecurity incident |
| Aug 26, 20268-K | Other events |
| Aug 3, 202610-Q | Quarterly report, Q2 2026 — revenue $5.44B (+8% y/y), net income $905.0M, EPS $0.61 |
| Jul 29, 20268-K | Earnings release — EPS $0.86 vs $0.83 est. (+3.6%); revenue $5.44B (+8% y/y) 0.0% |
| Jul 27, 20268-K | Exit or disposal costs |
| May 18, 20268-K | Boston Scientific enters into $2 billion accelerated share repurchase agreementOther events |
| May 18, 20268-K | Boston Scientific announces strategic investment in MiRus LLCOther events |
| May 5, 20268-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 1, 202610-Q | Quarterly report, Q1 2026 — revenue $5.20B (+12% y/y), net income $1.34B, EPS $0.90 |
| Apr 22, 20268-K | Earnings release — EPS $0.80 vs $0.80 est. (+0.0%); revenue $5.20B (+12% y/y) 9.0% |
| Mar 30, 20268-K | HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolismOther events |
| Mar 18, 2026DEFA14A | Additional proxy materials |
| Mar 18, 2026DEF 14A | Proxy statement |
| Mar 18, 2026ARS | Annual report to shareholders |
| Mar 6, 2026PRE 14A | Preliminary proxy statement |
| Feb 26, 20268-K | Material definitive agreement; Termination of a material agreement; New financial obligation |
| Feb 23, 20268-K | Boston Scientific elects Cathy Smith and Christophe Weber to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure; Other events |
| Feb 17, 202610-K | Annual report, FY2025 — revenue $20.07B (+20% y/y), net income $2.89B, EPS $1.94 |
| Feb 5, 20268-K | Directors or officers; compensation |
| Feb 4, 20268-K | Earnings release — EPS $0.80 vs $0.78 est. (+2.6%); revenue $5.29B (+16% y/y) 17.6% |
| Jan 15, 20268-K | Material definitive agreement |
| Jan 15, 20268-K | Boston Scientific announces agreement to acquire Penumbra, Inc.Regulation FD disclosure |
2025 · 20 filings
| Filed | What it is |
|---|---|
| Nov 19, 20258-K | Directors or officers; compensation |
| Nov 3, 202510-Q | Quarterly report, Q3 2025 — revenue $5.07B (+20% y/y), net income $755.0M, EPS $0.51 |
| Oct 23, 20258-K | Directors or officers; compensation |
| Oct 22, 20258-K | Earnings release — EPS $0.75 vs $0.71 est. (+5.6%); revenue $5.07B (+20% y/y) 4.0% |
| Sep 4, 20258-K | Directors or officers; compensation |
| Aug 1, 202510-Q | Quarterly report, Q2 2025 — revenue $5.06B (+23% y/y), net income $795.0M, EPS $0.53 |
| Jul 23, 20258-K | Results of operations |
| May 28, 20258-K | Other events |
| May 6, 20258-K | Shareholder vote results |
| May 1, 202510-Q | Quarterly report, Q1 2025 — revenue $4.66B (+21% y/y), net income $672.0M, EPS $0.45 |
| Apr 23, 20258-K | Directors or officers; compensation; Other events |
| Apr 23, 20258-K | Results of operations |
| Mar 19, 2025DEFA14A | Additional proxy materials |
| Mar 19, 2025DEF 14A | Proxy statement |
| Mar 19, 2025ARS | Annual report to shareholders |
| Feb 26, 20258-K | Material definitive agreement; New financial obligation; Other events |
| Feb 18, 202510-K | Annual report, FY2024 — revenue $16.75B (+18% y/y), net income $1.85B, EPS $1.25 |
| Feb 12, 20258-K | Directors or officers; compensation |
| Feb 5, 20258-K | Results of operations |
| Jan 16, 20258-K | Other events |
2024 · 25 filings
| Filed | What it is |
|---|---|
| Nov 22, 20248-K | Directors or officers; compensation |
| Nov 15, 20248-K | Other events |
| Nov 7, 20248-K | Regulation FD disclosure |
| Nov 1, 202410-Q | Quarterly report, Q3 2024 — revenue $4.21B (+19% y/y), net income $468.0M, EPS $0.32 |
| Oct 23, 20248-K | Results of operations |
| Aug 1, 202410-Q | Quarterly report, Q2 2024 — revenue $4.12B (+14% y/y), net income $322.0M, EPS $0.22 |
| Jul 30, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Jul 24, 20248-K | Results of operations |
| May 10, 20248-K | Directors or officers; compensation; Charter, bylaws or fiscal-year change; Regulation FD disclosure; Other events |
| May 6, 20248-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 1, 202410-Q | Quarterly report, Q1 2024 — revenue $3.86B (+14% y/y), net income $493.0M, EPS $0.33 |
| Apr 29, 2024DEFA14A | Additional proxy materials |
| Apr 24, 20248-K | Results of operations |
| Apr 4, 20248-K | Other events |
| Mar 20, 2024DEFA14A | Additional proxy materials |
| Mar 20, 2024DEF 14A | Proxy statement |
| Mar 20, 2024ARS | Annual report to shareholders |
| Mar 8, 2024PRE 14A | Preliminary proxy statement |
| Feb 27, 20248-K | Material definitive agreement; New financial obligation; Other events |
| Feb 21, 202410-K/A | Annual report, amended |
| Feb 20, 202410-K | Annual report, FY2023 — revenue $14.24B (+12% y/y), net income $1.59B, EPS $1.07 |
| Jan 31, 20248-K | Directors or officers; compensation |
| Jan 31, 20248-K | Results of operations |
| Jan 8, 20248-K | Material definitive agreement |
| Jan 8, 20248-K | Regulation FD disclosure |
2023 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
| Filed | What it is |
|---|---|
| Nov 1, 202310-Q | Quarterly report, Q3 2023 — revenue $3.53B (+11% y/y), net income $504.0M, EPS $0.34 |
| Aug 3, 202310-Q | Quarterly report, Q2 2023 — revenue $3.60B (+11% y/y), net income $270.0M, EPS $0.18 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $3.39B (+12% y/y), net income $314.0M, EPS $0.21 |
| Mar 23, 2023DEFR14A | Proxy statements |
| Mar 22, 2023DEFA14A | Additional proxy materials |
| Mar 22, 2023DEF 14A | Proxy statement |
| Mar 22, 2023ARS | Annual report to shareholders |
| Feb 23, 202310-K | Annual report, FY2022 — revenue $12.68B (+7% y/y), net income $698.0M, EPS $0.45 |
10 current reports (8-K) not listed; the year is on EDGAR.
2022 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202210-Q | Quarterly report, Q3 2022 — revenue $3.17B (+8% y/y), net income $188.0M, EPS $0.12 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $3.24B (+5% y/y), net income $260.0M, EPS $0.17 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $3.03B (+10% y/y), net income $110.0M, EPS $0.07 |
| Mar 23, 2022DEFA14A | Additional proxy materials |
| Mar 23, 2022DEF 14A | Proxy statement |
| Feb 23, 202210-K | Annual report, FY2021 — revenue $11.89B (+20% y/y), net income $1.04B, EPS $0.69 |
11 current reports (8-K) not listed; the year is on EDGAR.
2021 · 25 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202110-Q | Quarterly report, Q3 2021 — revenue $2.93B (+10% y/y), net income $419.0M, EPS $0.28 |
| Aug 6, 202110-Q | Quarterly report, Q2 2021 — revenue $3.08B (+54% y/y), net income $186.0M, EPS $0.12 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $2.75B (+8% y/y), net income $341.0M, EPS $0.23 |
| Mar 24, 2021DEFA14A | Additional proxy materials |
| Mar 24, 2021DEF 14A | Proxy statement |
| Feb 23, 202110-K | Annual report, FY2020 — revenue $9.91B (−8% y/y), net income −$82.0M, EPS −$0.08 |
19 current reports (8-K) not listed; the year is on EDGAR.
2020 · 31 filings — 24 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 5, 202010-Q | Quarterly report, Q3 2020 — revenue $2.66B (−2% y/y), net income −$155.0M, EPS −$0.12 |
| Aug 5, 202010-Q | Quarterly report, Q2 2020 — revenue $2.00B (−24% y/y), net income −$147.0M, EPS −$0.11 |
| May 6, 202010-Q | Quarterly report, Q1 2020 — revenue $2.54B (+2% y/y), net income $11.0M, EPS $0.01 |
| Apr 10, 2020DEFA14A | Additional proxy materials |
| Mar 25, 2020DEFA14A | Additional proxy materials |
| Mar 25, 2020DEF 14A | Proxy statement |
| Feb 25, 202010-K | Annual report, FY2019 — revenue $10.73B (+9% y/y), net income $4.70B, EPS $3.33 |
24 current reports (8-K) not listed; the year is on EDGAR.
2019 · 34 filings — 25 × 8-K, 3 × 10-Q, 3 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 5, 201910-Q | Quarterly report, Q3 2019 — revenue $2.71B (+13% y/y), net income $126.0M, EPS $0.09 |
| Jul 30, 201910-Q | Quarterly report, Q2 2019 — revenue $2.63B (+6% y/y), net income $154.0M, EPS $0.11 |
| May 3, 2019DEFA14A | Additional proxy materials |
| Apr 29, 201910-Q | Quarterly report, Q1 2019 — revenue $2.49B (+5% y/y), net income $424.0M, EPS $0.30 |
| Apr 22, 2019DEFA14A | Additional proxy materials |
| Mar 27, 2019DEFA14A | Additional proxy materials |
| Mar 27, 2019DEF 14A | Proxy statement |
| Mar 14, 2019PRE 14A | Preliminary proxy statement |
| Feb 19, 201910-K | Annual report, FY2018 — revenue $9.82B (+9% y/y), net income $1.67B, EPS $1.19 |
25 current reports (8-K) not listed; the year is on EDGAR.
2018 · 26 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 29, 201810-Q | Quarterly report, Q3 2018 — revenue $2.39B (+8% y/y), net income $432.0M, EPS $0.31 |
| Jul 31, 201810-Q | Quarterly report, Q2 2018 — revenue $2.49B (+10% y/y), net income $555.0M, EPS $0.40 |
| May 1, 201810-Q | Quarterly report, Q1 2018 — revenue $2.38B (+8% y/y), net income $298.0M, EPS $0.21 |
| Mar 28, 2018DEFA14A | Additional proxy materials |
| Mar 28, 2018DEF 14A | Proxy statement |
| Feb 20, 201810-K | Annual report, FY2017 — revenue $9.05B (−0% y/y), net income $104.0M, EPS $0.08 |
20 current reports (8-K) not listed; the year is on EDGAR.
2017 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 2, 201710-Q | Quarterly report, Q3 2017 — revenue $2.22B (+6% y/y), net income $283.0M, EPS $0.20 |
| Aug 3, 201710-Q | Quarterly report, Q2 2017 — revenue $2.26B (+6% y/y), net income $146.0M, EPS $0.11 |
| May 3, 201710-Q | Quarterly report, Q1 2017 — revenue $2.20B (+10% y/y), net income $290.0M, EPS $0.21 |
| Mar 28, 2017DEFA14A | Additional proxy materials |
| Mar 28, 2017DEF 14A | Proxy statement |
| Mar 17, 201710-K/A | Annual report, amended |
| Feb 23, 201710-K | Annual report, FY2016 — revenue $9.08B (+12% y/y), net income $347.0M, EPS $0.25 |
15 current reports (8-K) not listed; the year is on EDGAR.
2016 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 24 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2014 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2013 · 24 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 5 other forms
Counted, not listed; the year is on EDGAR.
2012 · 22 filings — 13 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
Counted, not listed; the year is on EDGAR.
2011 · 27 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2010 · 28 filings — 21 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2009 · 31 filings — 24 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2008 · 26 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 30 filings — 23 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2006 · 33 filings — 27 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 27 filings — 21 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2004 · 25 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 13 filings — 5 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2000 · 5 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1999 · 14 filings — 3 × 10-K/A, 3 × 10-Q, 3 × 10-Q/A and 4 other forms
Counted, not listed; the year is on EDGAR.
1998 · 13 filings — 4 × 8-K, 3 × 10-Q, 2 × DEF 14A and 4 other forms
Counted, not listed; the year is on EDGAR.
1997 · 7 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-Q/A and 2 other forms
Counted, not listed; the year is on EDGAR.
1996 · 5 filings — 3 × 10-Q, 1 × 8-K, 1 × 8-K/A
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 73 filings — 48 × 4, 9 × 425, 3 × SCHEDULE 13G/A and 12 other forms
| Filed | What it is |
|---|---|
| Sep 3, 20264 | Insider transaction (Form 4) |
| Aug 26, 20264 | Insider transaction (Form 4) |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 11, 20264 | Insider transaction (Form 4) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 6, 2026SCHEDULE 13G/A | Other filings |
| Aug 5, 20264 | Insider transaction (Form 4) |
| Aug 5, 20264 | Insider transaction (Form 4) |
| Aug 3, 20264 | Insider transaction (Form 4) |
| Aug 3, 20264 | Insider transaction (Form 4) |
| Jul 2, 20264 | Insider transaction (Form 4) |
| Jun 24, 202611-K | Employee plan annual report |
| Jun 1, 20264 | Insider transaction (Form 4) |
| May 21, 20264 | Insider transaction (Form 4) |
| May 21, 20264 | Insider transaction (Form 4) |
| May 21, 20264 | Insider transaction (Form 4) |
| May 21, 2026SD | Specialized disclosure (conflict minerals) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
| May 11, 20264 | Insider transaction (Form 4) |
The newest 25 of 73 shown; the full year is on EDGAR.
2025 · 139 filings — 84 × 4, 42 × 144, 3 × 3 and 8 other forms
| Filed | What it is |
|---|---|
| Dec 8, 20253 | Initial insider holdings (Form 3) |
| Dec 2, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 6, 20254 | Insider transaction (Form 4) |
| Nov 6, 2025144/A | Notice of proposed sale (Form 144), amended |
| Nov 4, 20254 | Insider transaction (Form 4) |
| Nov 3, 2025144 | Notice of proposed sale (Form 144) |
| Oct 31, 20254 | Insider transaction (Form 4) |
| Oct 31, 20254 | Insider transaction (Form 4) |
| Oct 28, 20254 | Insider transaction (Form 4) |
| Oct 28, 2025144 | Notice of proposed sale (Form 144) |
| Oct 27, 2025144 | Notice of proposed sale (Form 144) |
| Oct 1, 20254 | Insider transaction (Form 4) |
| Oct 1, 2025144 | Notice of proposed sale (Form 144) |
| Sep 3, 20254 | Insider transaction (Form 4) |
| Sep 2, 2025144 | Notice of proposed sale (Form 144) |
| Aug 6, 2025SCHEDULE 13G/A | Other filings |
| Aug 4, 20254 | Insider transaction (Form 4) |
| Aug 4, 20254 | Insider transaction (Form 4) |
| Aug 4, 20254 | Insider transaction (Form 4) |
| Aug 4, 20254 | Insider transaction (Form 4) |
| Aug 1, 2025144 | Notice of proposed sale (Form 144) |
| Aug 1, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 139 shown; the full year is on EDGAR.
2024 · 160 filings — 107 × 4, 40 × 144, 4 × SC 13G/A and 7 other forms
| Filed | What it is |
|---|---|
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 2, 20244 | Insider transaction (Form 4) |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 26, 20244 | Insider transaction (Form 4) |
| Nov 25, 20244 | Insider transaction (Form 4) |
| Nov 25, 2024144 | Notice of proposed sale (Form 144) |
| Nov 22, 20244 | Insider transaction (Form 4) |
| Nov 21, 2024144 | Notice of proposed sale (Form 144) |
| Nov 13, 20244 | Insider transaction (Form 4) |
| Nov 12, 20244 | Insider transaction (Form 4) |
| Nov 8, 2024144 | Notice of proposed sale (Form 144) |
| Nov 7, 20244 | Insider transaction (Form 4) |
| Nov 5, 2024144 | Notice of proposed sale (Form 144) |
| Nov 4, 20244 | Insider transaction (Form 4) |
| Nov 1, 2024144 | Notice of proposed sale (Form 144) |
| Oct 8, 20244 | Insider transaction (Form 4) |
| Oct 8, 20244 | Insider transaction (Form 4) |
| Oct 7, 2024144 | Notice of proposed sale (Form 144) |
| Oct 7, 2024144 | Notice of proposed sale (Form 144) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 1, 2024144 | Notice of proposed sale (Form 144) |
| Sep 6, 20244 | Insider transaction (Form 4) |
| Sep 5, 2024144 | Notice of proposed sale (Form 144) |
| Sep 3, 20244 | Insider transaction (Form 4) |
The newest 25 of 160 shown; the full year is on EDGAR.
2023 · 140 filings — 102 × 4, 26 × 144, 6 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2022 · 161 filings — 147 × 4, 4 × SC 13G/A, 3 × SC 13G and 7 other forms
Counted, not listed; the year is on EDGAR.
2021 · 180 filings — 169 × 4, 4 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2020 · 167 filings — 145 × 4, 5 × 424B5, 4 × SC 13G/A and 10 other forms
Counted, not listed; the year is on EDGAR.
2019 · 177 filings — 158 × 4, 5 × SC 13G/A, 2 × 4/A and 9 other forms
Counted, not listed; the year is on EDGAR.
2018 · 159 filings — 145 × 4, 6 × SC 13G/A, 2 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2017 · 158 filings — 147 × 4, 5 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2016 · 169 filings — 144 × 4, 5 × UPLOAD, 4 × SC 13G/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2015 · 169 filings — 147 × 4, 6 × 3, 5 × SC 13G/A and 9 other forms
Counted, not listed; the year is on EDGAR.
2014 · 129 filings — 117 × 4, 4 × SC 13G/A, 3 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2013 · 127 filings — 108 × 4, 3 × 3, 3 × SC 13G and 10 other forms
Counted, not listed; the year is on EDGAR.
2012 · 187 filings — 180 × 4, 3 × SC 13G/A, 2 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2011 · 132 filings — 111 × 4, 5 × 3, 4 × SC 13G/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2010 · 418 filings — 401 × 4, 6 × 3, 4 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2009 · 294 filings — 265 × 4, 11 × 4/A, 6 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2008 · 189 filings — 165 × 4, 7 × SC 13G/A, 4 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2007 · 138 filings — 99 × 4, 6 × SC TO-C, 5 × SC 13G and 10 other forms
Counted, not listed; the year is on EDGAR.
2006 · 156 filings — 90 × 4, 31 × 425, 6 × 3 and 16 other forms
Counted, not listed; the year is on EDGAR.
2005 · 140 filings — 107 × 4, 11 × 425, 5 × SC 13G/A and 12 other forms
Counted, not listed; the year is on EDGAR.
2004 · 131 filings — 111 × 4, 5 × 3, 5 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2003 · 138 filings — 124 × 4, 3 × SC 13G, 3 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2002 · 57 filings — 36 × 4, 4 × SC 13G/A, 3 × SC 13G and 10 other forms
Counted, not listed; the year is on EDGAR.
2001 · 14 filings — 3 × SC TO-T/A, 2 × S-8, 2 × SC TO-C and 7 other forms
Counted, not listed; the year is on EDGAR.
2000 · 5 filings — 2 × SC 13G/A, 1 × 11-K, 1 × S-8 and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 9 filings — 4 × 424B2, 2 × S-3/A, 2 × SC 13G/A and 1 other form
Counted, not listed; the year is on EDGAR.
1998 · 17 filings — 6 × SC 13G/A, 2 × S-3, 2 × SC 13D and 7 other forms
Counted, not listed; the year is on EDGAR.
1997 · 9 filings — 3 × SC 13G, 2 × S-8, 1 × 11-K and 3 other forms
Counted, not listed; the year is on EDGAR.
1996 · 3 filings — 2 × 11-K, 1 × SC 13G/A
Counted, not listed; the year is on EDGAR.
1995 · 1 filing — 1 × SC 13G
Counted, not listed; the year is on EDGAR.
About this data#
Boston Scientific Corporation (BSX) has 4,791 filings on EDGAR going back to 1995: 36 annual reports, 97 quarterly reports and 430 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 17, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 7, 2026, furnished a press release headed “Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer”. Over the last 13 months insiders sold $15.0M in 1 sale and bought $10.0M in 10 purchases; 153 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Boston Scientific Corporation, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read BSX's latest 10-K?
- BSX's latest annual report, a 10-K, was filed on Feb 17, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did BSX last file an 8-K?
- On Oct 7, 2026 it furnished a press release headed “Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 29, 2026.
- Are BSX insiders buying or selling?
- Over the last 13 months insiders sold $15.0M in 1 sale and bought $10.0M in 10 purchases; 153 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Mahoney Michael F (Chairman, President & CEO · Director) sold 160,901 shares on Feb 2, 2026 for $15.0M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has BSX made?
- 4,791 filings are on EDGAR under the registrant records that have been Boston Scientific Corporation, going back to 1995; 3,692 of them are insider ownership forms (Forms 3, 4, 5 and 144).